Navigation Links
NeuroRx Awarded FDA Fast Track Designation for First Drug Regimen Targeting Suicide in Bipolar Depression
Date:9/6/2017

WILMINGTON, Del., Sept. 6, 2017 /PRNewswire/ -- NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast Track status by the US Food and Drug Administration for its sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin enrolling patients in a pivotal trial of this sequential therapy targeting patients who are admitted to Emergency Departments with ASIB in bipolar depression.1

Jonathan C. Javitt, MD, MPH, CEO, NeuroRx, Inc.
Jonathan C. Javitt, MD, MPH, CEO, NeuroRx, Inc.
NeuroRx phase 2 results of NRX-100 (ketamine) followed by NRX-101 (D-cycloserine + lurasidone) demonstrating 50% reduction in symptoms of depression, accompanied by 75% reduction in suicidal ideation. Adapted from Kantrowitz, et. al.,Journal of Clinical Psychiatry, 2015
NeuroRx phase 2 results of NRX-100 (ketamine) followed by NRX-101 (D-cycloserine + lurasidone) demonstrating 50% reduction in symptoms of depression, accompanied by 75% reduction in suicidal ideation. Adapted from Kantrowitz, et. al.,Journal of Clinical Psychiatry, 2015

Fast Track Designation is awarded by the FDA to investigational drugs that are deemed by FDA to treat a serious medical condition and for which there is preclinical and/or clinical data to demonstrate that the drug has the potential to address an unmet medical need. Suicidality in Bipolar Depression is a condition for which there is currently no approved drug therapy and for which the only FDA-approved treatment is Electroconvulsive Therapy (ECT).

Jonathan Javitt, M.D., M.P.H., the Company's Chief Executive Officer, will update investors on the Company's progress towards the planned October 2017 initiation of its upcoming clinical trial and recently issued claims at the upcoming Rodman and Renshaw Global Investment Conference, being held on September 11 and 12 at the New York Palace Hotel. In addition, the company is available to conduct one-on-one meetings with registered attendees of the conference. The presentation will be webcast.

Rodman and Renshaw Global Investment Conference Presentation Details

Date:

Tuesday, September 12

Time:

5:30 PM Eastern Time

About Bipolar Depression and Acute Suicidal Ideation & Behavior

Bipolar disorder, which affects 5.7 million Americans, is characterized by significant changes in mood, from mania or hypomania, to depression, often quite severe. The depressive phase, which is called "bipolar depression" can trigger thoughts of suicidal thoughts and behaviors. Standard of care consists of hospitalized observation and electroconvulsive therapy (ECT). Unfortunately, most commonly used antidepressants bear an FDA-mandated warning label identifying the potential to increase the risk of suicide.

Each day, approximately 100 Americans, and more than 2,100 people worldwide, end their lives by suicide, according to American Foundation for Suicide Prevention (AFSP) and the World Health Organization (WHO). Although only 10% of all people with depression have bipolar depression, NeuroRx estimates that bipolar depression accounts for nearly half of all suicides each year.

About NRX-101

NRX-101 is a patented, oral, fixed-dose combination of two FDA-approved drugs: d-cycloserine, a N-methyl-D-aspartate (NMDA) receptor modulator, and lurasidone, a 5-HT2a receptor antagonist. NeuroRx's investigational treatment approach begins with a single dose of NRX-100 (ketamine), an FDA-approved anesthetic, for initial stabilization, followed by approximately six weeks of daily oral NRX-101. Results from two Phase II clinical studies, involving 26 and 8 patients respectively, have been published in peer-reviewed journals. Findings showed a 50% reduction in symptoms of depression and a 75% reduction in suicidal ideation in bipolar patients who were on background antidepressant therapy and then treated with d-cycloserine, one of the active ingredients in NRX-101.

About NeuroRx, Inc.

NeuroRx draws upon 30 years of basic science and clinical expertise in the role of the N-methyl-D-aspartate (NMDA), a receptor that regulates human thought processes, particularly depression and suicidality. The company is privately funded and led by former senior executives of Johnson and Johnson, Pfizer, Lilly, and Bristol Meyer Squibb.

Learn more at NeuroRxpharma.com.

Contact:
Investor Relations:
Michael Rice                                                  
LifeSci Advisors, LLC                                  
+1-917-282-3242                                           
mrice@LifeSciAdvisors.com                         

PR:
Deanne Eagle
Planet Communications
+1-917-837-5866
175105@email4pr.com

1 Details of the clinical trial may be viewed on www.clinicaltrials.gov under the identifier NCT02974010.

View original content with multimedia:http://www.prnewswire.com/news-releases/neurorx-awarded-fda-fast-track-designation-for-first-drug-regimen-targeting-suicide-in-bipolar-depression-300514652.html


'/>"/>
SOURCE NeuroRx, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. NeuroRx Announces First Human Trial Results Targeting Sustained Treatment of Bipolar Depression & Suicidality
2. American Psychiatric Association Task Force Report Identifies Potential Value of NeuroRx Active Ingredient for Treatment of Depression
3. NeuroRx announces FDA IND clearance for NRX-101 phase 2b/3 study and publication of promising biomarker data
4. AnaptysBio Awarded U.S. Government Contract To Develop Anti-Ricin Antibodies
5. Cempra Awarded $58 Million Contract to Develop Antibiotic for Pediatric Use and Biodefense by Biomedical Advanced Research and Development Authority (BARDA)
6. Oramed Pharmaceuticals Awarded Grant by the Office of the Chief Scientist of Israel
7. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
8. Tunitas Therapeutics Awarded Phase II SBIR Grant to Advance Asthma Program
9. Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies
10. Great Lakes NeuroTechnologies Awarded Patent For Technology To Treat Parkinsons Disease With Brain Stimulation During Sleep
11. Instrumentation Laboratory Awarded Premier Healthcare Alliance Contract For Hemostasis Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/9/2018)... ... , ... Autism is a developmental disorder affecting more than 3.5 million Americans’ ... in 68 people have the disorder), chances are you know someone on the autism ... with autism methods of communication and tactics to interact with others. These options help ...
(Date:8/7/2018)... ... August 06, 2018 , ... Drs. Jonathan and ... MS using laser dentistry techniques. Using their BIOLASE WaterLase® dental laser, this modern ... REPAIR Perio™. , Affecting the lives of millions of Americans, gum disease can ...
(Date:8/7/2018)... ... August 07, 2018 , ... ... role of Sanarus Technologies President, effective immediately. Mr. Stark will lead all ... experience in medical device toward finding new and innovative ways to advance ...
Breaking Medicine Technology:
(Date:8/15/2018)... , ... August 15, 2018 , ... Today David Hyde ... Kickstarter. , Born out of a desire for confidence and comfort year-round, ... and body odor – even in the hottest, most humid of climates. , The ...
(Date:8/14/2018)... ... August 14, 2018 , ... Gastro Health, LLC (“Gastro ... for healthcare executives Simon Frisch and Chris Weinstein, who have been appointed Senior ... roles at a time of tremendous growth for the group, which has increased ...
(Date:8/11/2018)... ... 2018 , ... Dr. Siavash Eftekhari, Oral and Maxillofacial Surgeon at Monarch ... outpost trip to deliver dental care in impoverished communities. Along with a team of ... his time to help deliver care to over 550 individuals in need. , This ...
(Date:8/9/2018)... (PRWEB) , ... August 09, 2018 , ... ... not realize their implants have ruptured, according to cross-referenced data from The American ... and silicone gel implant rupture rates monitored by the FDA. As an MRI ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... Kathy Coover and the company’s independent distributors, customers, and employees, the newly established ... of fundraising, exceeding the $2 million goal. 100 percent of the donations will ...
Breaking Medicine News(10 mins):